PDX Model Cohort
HER2+ PDX Models
A meticulously curated bank of Patient-Derived Xenograft (PDX) HER2 mouse models, directly established from patient biopsies, featuring well-documented treatment histories, genomic mutations, and clinical characteristics.
Summary
Champions Oncology has developed a cutting-edge cohort of HER2/ERBB2 Patient-derived Xenograft models, delivering a full-spectrum approach to HER2/ERBB2 cancers, including breast, gastric, and salivary duct carcinomas, as well as in other forms of cancer. Our bank consists of a large bank of approximately 1400* extensively characterized patient-derived xenograft (PDX) models for oncology drug development. Our models are well-annotated with patient treatment history and molecular characterizations such as mutations, gene expression, and copy number variations of the HER2 family of genes.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading HER2+ cohort showcases low-passage PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to a large bank of HER2 mouse models with clinically relevant molecular and pathological characteristics.
Access to highly characterized models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
Includes models pretreated with advanced therapies such as immunotherapies, small molecule inhibitors, and more.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes